Raj Mathur, MD
Geriatric Medicine · Washington, DCNPI 1992864177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 64.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $1,284 and has fallen 68.8% since, to $400 in 2025.
Across 153 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$575
- GSK$330
- Ironwood Pharmaceuticals, Inc$137
- Zealand Pharma US, Inc.$125
- Lilly USA, LLC$95
- plus $565 from 12 others
What the payments were for
- Food & beverage$5,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $3,385 |
| Novo Nordisk | 10 | $575 |
| GSK | 17 | $330 |
| Ironwood Pharmaceuticals, Inc | 9 | $137 |
| Zealand Pharma US, Inc. | 1 | $125 |
| Lilly USA, LLC | 4 | $95 |
| Novartis | 5 | $93 |
| Amgen | 4 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Johnson & Johnson | 3 | $51 |
| Bayer | 2 | $45 |
| Pfizer | 2 | $43 |
| AbbVie | 2 | $41 |
| Boehringer Ingelheim | 1 | $35 |
| Exact Sciences | 1 | $28 |
| Abbott | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few geriatric medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $65,309 |
| LinzessLinaclotide | 41 | $61,908 |
| JardianceEmpagliflozin | 21 | $35,737 |
| EliquisApixaban | 24 | $34,802 |
| TivicayDolutegravir Sodium | 14 | $31,773 |
| JanuviaSitagliptin Phosphate | 27 | $30,396 |
| EntrestoSacubitril/Valsartan | 16 | $27,681 |
| FarxigaDapagliflozin Propanediol | 16 | $25,789 |
| OzempicSemaglutide | 14 | $24,667 |
| TrulicityDulaglutide | 17 | $21,290 |
| EdurantRilpivirine Hcl | 14 | $20,524 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,834 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $9,021 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $6,967 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $5,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga | $3,385 | $91,09975 claims |
| AbbVieLinzess | $41 | $61,90841 claims |
| Boehringer IngelheimJardiance | $35 | $35,73721 claims |
| PfizerEliquis | $43 | $34,80224 claims |
| NovartisEntresto | $93 | $27,68116 claims |
| Novo NordiskOzempic | $575 | $24,66714 claims |
| Lilly USA, LLCTrulicity | $95 | $21,29017 claims |
| GSKAnoro Ellipta | $330 | $9,83412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Washington
- Thomas ObisesanWashington$41K
- Victoria FedorovaWashington$997
- Mikhail KoganWashington$649
- Elizabeth CobbsWashington$236
- Karen BlackstoneWashington$135
- Guy Vin ChangWashington$132
- Paul RhodesWashington$122
- Stephanie BruceWashington$36
- Tania AlchalabiWashington$28
- Austin ArmstrongWashington$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.